Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer

• Published in: Journal of gastrointestinal surgery 2019-06, Vol.23 (6), p.1166-1171
• Main Authors: Rashid, M. Farzan, Jackson, Terri L., Morgan, Jheanell A., Dwyer, Franklin A., Schrope, Beth A., Chabot, John A., Kluger, Michael D.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Aged; Anticoagulants; Antithrombins - administration & dosage; Bone surgery; Dabigatran - administration & dosage; Female; Gastroenterology; Gastrointestinal surgery; Health risk assessment; Humans; Male; Medicine; Medicine & Public Health; Original Article; Pancreatectomy - adverse effects; Pancreatic cancer; Pancreatic Neoplasms - surgery; Postoperative Complications - etiology; Postoperative Complications - prevention & control; Quality control; Surgery; Thromboembolism; Treatment Outcome; Venous Thromboembolism - etiology; Venous Thromboembolism - prevention & control
• ISSN: 1091-255X; 1873-4626
• DOI: 10.1007/s11605-018-3936-1

Background The American College of Chest Physicians and American Hepato-Pancreato-Biliary Association recommend using low-molecular-weight heparin for 28 days postoperatively for venous thromboembolism prophylaxis after cancer surgery. Dabigatran is a once daily oral anticoagulant that is FDA approved for venous thromboembolism prophylaxis after orthopedic surgery, uses fixed dosing, and has an antidote. Methods Patients undergoing surgery for malignant pancreatic tumors (neuroendocrine excluded) from January 2017 to January 2018 were converted to dabigatran 220 mg daily on discharge until postoperative day 28; patients with medical or insurance contraindications were converted to enoxaparin or another direct oral anticoagulant. The primary endpoint was bleeding complications through 90 days. Results A total of 134 patients were considered for this study (median age 67 ± 10; 58.9% male). Eighty-seven (82.9%) patients received dabigatran and 18 (17.1%) received another form of anticoagulation. There were 19 (4.2%) patients not prescribed dabigatran due to medical or inpatient contraindications. Four patients experienced bleeding complications after discharge while on dabigatran. Two (2%) were major bleeds (Clavien-Dindo IV and V), and 2 (2%) were minor (Clavien-Dindo I). Patient compliance was excellent, with 93% of prescribed patients fully completing their prophylaxis. There were 2 patients that developed symptomatic deep vein thrombosis. Conclusion The use of a direct oral anticoagulant as extended venous thromboembolism prophylaxis after major gastrointestinal surgery has not been studied to date. These results show dabigatran to be a safe alternative to low-molecular-weight heparin for extended venous thromboembolism prophylaxis with regard to bleeding complications.